Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07683195
Enrolling by invitation Observational

Research on Early Recurrence of Locally Advanced Gastric Cancer Based on CT Radiomics Prediction

NCT07683195 · tracked via the Priya Life Science China tracker
Sponsor
Liu Yang
Phase
Observational
Started
2020-01-01
Last updated
2026-07-07

Condition(s) studied

Gastric Cancer

Study summary

This study aims to develop a model for predicting postoperative recurrence in patients with LAGC using artificial intelligence (AI) technology based on preoperative computed tomography (CT) images

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. pathology diagnosis of LAGC (pT2NxM0-pT4NxM0); 2. radical gastrectomy with D2 lymph node dissection (\>15 lymph nodes); 3. available clinicopathological data; 4. patients underwent contrast-enhanced abdominal CT scans within 4 weeks before surgery. Exclusion Criteria: 1. preoperative treatment for LAGC (radiotherapy, chemotherapy, or systemic therapy); 2. previous malignancies; 3. unsatisfactory gastric distention or inability to identify the primary tumor; 4. image artifacts.

Primary outcome measure(s)

  • Accuracy of early recurrence models — Immediately evaluated after the early recurrence model was built
    In this study, clinical data and contrast-enhanced CT imaging data of 550 patients with locally advanced gastric cancer from our hospital were collected. Machine learning and deep learning algorithms were applied to assess the early recurrence of patients within one year after surgery. The performance of the artificial intelligence model was evaluated from two dimensions: diagnostic accuracy and stability, and quantitative analysis of its performance was conducted using indicators including the area under the curve (AUC) and the precision-recall curve (PR curve).

Trial sites (1)

FacilityCityRegionStatus
QianfoshanH Jinan Shandong

More Liu Yang trials in China

Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer Starting soon

Other trials for the same condition

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore Recruiting
Study for AZD4360 in Participants With Advanced Solid Tumours Active, not recruiting
Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site Recruiting
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30) Recruiting
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07683195 on ClinicalTrials.gov ↗ ← All trials in China